Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by WD Rutherford LLC

WD Rutherford LLC decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 6.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,628 shares of the medical research company’s stock after selling 936 shares during the quarter. WD Rutherford LLC’s holdings in Charles River Laboratories International were worth $2,815,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of CRL. Headlands Technologies LLC acquired a new position in shares of Charles River Laboratories International in the first quarter worth about $41,000. VisionPoint Advisory Group LLC increased its holdings in Charles River Laboratories International by 45.1% in the fourth quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock valued at $49,000 after buying an additional 65 shares during the last quarter. Brown Brothers Harriman & Co. increased its holdings in Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after buying an additional 95 shares during the last quarter. GAMMA Investing LLC bought a new stake in Charles River Laboratories International in the fourth quarter valued at about $62,000. Finally, Concord Wealth Partners increased its holdings in Charles River Laboratories International by 362.5% in the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after buying an additional 203 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the subject of several research analyst reports. StockNews.com raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Tuesday, August 20th. Baird R W lowered Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. TD Cowen reduced their price objective on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research report on Monday, August 12th. Mizuho began coverage on Charles River Laboratories International in a research report on Friday, June 7th. They set a “neutral” rating and a $235.00 price objective for the company. Finally, Argus reiterated a “hold” rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. Ten analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and an average price target of $231.00.

Charles River Laboratories International Stock Up 2.0 %

Shares of CRL stock traded up $3.94 on Friday, reaching $205.27. 595,201 shares of the company’s stock traded hands, compared to its average volume of 588,516. The company has a market capitalization of $10.57 billion, a P/E ratio of 24.15, a price-to-earnings-growth ratio of 2.32 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. The business’s 50 day moving average price is $212.72 and its two-hundred day moving average price is $230.10.

Charles River Laboratories International announced that its Board of Directors has authorized a share repurchase program on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).